Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Nammi Therapeutics Inc
Exscientia AI Limited
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
Agenus Inc.
National Cancer Institute (NCI)
Orano Med LLC
ViroMissile, Inc.
Tizona Therapeutics, Inc
Angiex, Inc.
IDEAYA Biosciences
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Phrontline Biopharma
Innate Pharma
NeoTX Therapeutics Ltd.
Nuvation Bio Inc.
Exelixis
3B Pharmaceuticals GmbH
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
NextPoint Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Columbia University
National Cancer Institute (NCI)
Carisma Therapeutics Inc
Astellas Pharma Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
NGM Biopharmaceuticals, Inc
Danatlas Pharmaceuticals Co., Ltd
Pfizer
Pfizer
NGM Biopharmaceuticals, Inc
OHSU Knight Cancer Institute
Pfizer
M.D. Anderson Cancer Center
Lebanese University
AstraZeneca
Xencor, Inc.
Impact Therapeutics, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.